Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence (Q26799079)

1

0 references

Roxana Mehran

5

object named as

Roxana Mehran

0 references

author name string

David Brieger

2

0 references

Anthony J Dalby

3

0 references

Seung-Jung Park

Journal of the American College of Cardiology

4

0 references

language of work or name

English

0 references

publication date

18 August 2015

0 references

published in

0 references

volume

66

0 references

page(s)

832-47

0 references

issue

7

0 references

cites work

Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Guidelines for the management of antiplatelet therapy in patients with coronary stents undergoing non-cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Atherothrombosis and high-risk plaque: part I: evolving concepts

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

1 reference

7 January 2021

A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

In-stent neoatherosclerosis: a final common pathway of late stent failure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

1 reference

7 January 2021

Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urge

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Stent thrombosis: a clinical perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Acute coronary syndrome without ST elevation: implementation of new guidelines

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Novel antiplatelet agents in acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Dual antiplatelet therapy after drug-eluting stents--how long to treat?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Duration of dual antiplatelet therapy after implantation of drug-eluting stents.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

A prospective natural-history study of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Vorapaxar in the secondary prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Bedside monitoring to adjust antiplatelet therapy for coronary stenting

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Long-term use of ticagrelor in patients with prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomize

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

2013 ESC guidelines on the management of stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribu

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Early and late effects of clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Late stent thrombosis after drug-eluting stent implantation for acute myocardial infarction: a new red flag is raised.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

Long-term secondary prevention after high-risk stenting: a good drug for a bad stent.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.05.053

7 January 2021